Awareness and clinical impact of the revised FDA warning on menopausal hormone therapy among Latin American physicians. REDLINC XIV
Authors:
- Juan E. BlümelJBJuan E. Blümel
- María S. VallejoMVMaría S. Vallejo
- Peter ChedrauiPCPeter Chedraui
- Hugo SalinasHSHugo Salinas
- Sócrates AedoSASócrates Aedo
- Ana L. Ribeiro ValadaresAVAna L. Ribeiro Valadares
- Ascanio BencosmeABAscanio Bencosme
- Carlos EscalanteCECarlos Escalante
- Claudia ReyCRClaudia Rey
- Daysi A. Navarro-DespaigneDNDaysi A. Navarro-Despaigne
- 6 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Menopause
Abstract
Objective: To evaluate Latin American physicians’ awareness regarding the recent revised statement of the US Food and Drug Administration (FDA) “black box warning” on menopausal hormone therapy (MHT) and to analyze its self-reported impact on clinical practice. Methods: A multicenter cross-sectional study was conducted in thirteen Latin American countries. Physicians caring for peri- and postmenopausal women completed an anonymous survey assessing awareness of the revised FDA communication, perceived clarity, self-reported impact on clinical practice, and MHT prescribing patterns. Bivariate analyses and multivariable logistic regression were performed. Results: A total of 2,166 physicians participated, mainly obstetrician-gynecologists (75.7%) and endocrinologists (9.0%). Overall, 80.7% were aware of the FDA revised statement. In addition, 90.5% considered that the previous warning had overestimated breast cancer risk, and 78.9% believed that the revised communication provides a more balanced view of risks and benefits. Changes in clinical practice were reported by 59.4% of participants, whereas 18.7% reported increased MHT prescribing. Furthermore, 53.3% modified the way they explain breast cancer risk, and 40.4% reported spending more time on patient education and shared decision-making. Physicians with ≤20 years of professional experience and those from specialties other than obstetrics and gynecology or endocrinology were more likely to report that the FDA revised statement would influence their therapeutic conduct. Conclusions: The revised FDA communication appears to have influenced Latin American physicians’ views and self-reported clinical practice, promoting a more balanced view of MHT and encouraging patient education and shared decision-making. However, the increase in MHT prescribing rates was relatively modest, and overall findings should be interpreted cautiously given the cross-sectional design, self-reported nature of the data, and potential selection bias.Keywords
This publication has 18 references indexed in Scilit:
- Menopausal Hormone Therapy Use Among Postmenopausal WomenJAMA Health Forum, 2024
- The 2022 hormone therapy position statement of The North American Menopause SocietyMenopause, 2022
- Menopausal hormone therapy: why we should no longer be afraid of the breast cancer riskClimacteric, 2022
- Hormone replacement therapy – where are we now?Climacteric, 2021
- Menopausal Hormone Therapy and Health Outcomes: Is Timing Everything?Clinical Chemistry, 2020
- Depression and MenopauseMedical Clinics of North America, 2019
- Menopause Management — Getting Clinical Care Back on TrackNew England Journal of Medicine, 2016
- Impaired quality of life among middle aged women: A multicentre Latin American studyMaturitas, 2008
- National Use of Postmenopausal Hormone TherapyJAMA, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002